Scholarlink

Objective <p>To investigate the anti-tumor effects and immuno-inflammatory-metabolic mechanisms of Buzhong Yiqi Granules (BYG) in alleviating cancer-related fatigue (CRF) in lung cancer.</p> Methods <p>UPLC-Q-TOF/MS detected compounds in BYG. CRF was induced in mice via Lewis lung carcinoma cell inoculation, with daily BYG treatment for 14&#xa0;days. Anti-fatigue efficacy was evaluated through behavioral tests and ATP content detection. Anti-tumor effects were assessed via histopathology, tumor volume, and weight. Immuno-inflammatory-metabolic mechanisms were evaluated using inflammatory cytokines (IL-6, TNF-α, IFN-γ) and immune cell subsets (CD4+, CD8+ T cells) in serum and tumor tissues.</p> Results <p>Ninety-four active compounds were identified in BYG. In the CRF mouse model, BYG prolonged swimming time, reduced tail suspension immobility, increased muscle ATP to exert anti-fatigue effects; it inhibited tumor growth and metastasis by reducing volume and downregulating EGFR/CD34/MMP-9; it also modulated inflammation and immunity by lowering IL-6/TNF-α, elevating IFN-γ, enhancing CD4 + T cells and restoring the CD4 + /CD8 + ratio.</p> Conclusions <p>BYG alleviates CRF via multi-target mechanisms involving energy metabolism, tumor inhibition, and immune-inflammatory regulation, supporting its clinical use in CRF and potential as lung cancer adjuvant therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-tumor effects and immuno-inflammatory-metabolic mechanisms of Buzhong Yiqi Granules in improving cancer-related fatigue in lung cancer

  • 期刊论文

  • 发表日期：

    2026年3月31日

查看全文
  • Shasha Mei,
  • Shuangli Peng,
  • Ziming Wang,
  • Zhenzhong Xia,
  • Aohan Hao,
  • Qiong Xiang,
  • Enfeng Song

摘要

Objective

To investigate the anti-tumor effects and immuno-inflammatory-metabolic mechanisms of Buzhong Yiqi Granules (BYG) in alleviating cancer-related fatigue (CRF) in lung cancer.

Methods

UPLC-Q-TOF/MS detected compounds in BYG. CRF was induced in mice via Lewis lung carcinoma cell inoculation, with daily BYG treatment for 14 days. Anti-fatigue efficacy was evaluated through behavioral tests and ATP content detection. Anti-tumor effects were assessed via histopathology, tumor volume, and weight. Immuno-inflammatory-metabolic mechanisms were evaluated using inflammatory cytokines (IL-6, TNF-α, IFN-γ) and immune cell subsets (CD4+, CD8+ T cells) in serum and tumor tissues.

Results

Ninety-four active compounds were identified in BYG. In the CRF mouse model, BYG prolonged swimming time, reduced tail suspension immobility, increased muscle ATP to exert anti-fatigue effects; it inhibited tumor growth and metastasis by reducing volume and downregulating EGFR/CD34/MMP-9; it also modulated inflammation and immunity by lowering IL-6/TNF-α, elevating IFN-γ, enhancing CD4 + T cells and restoring the CD4 + /CD8 + ratio.

Conclusions

BYG alleviates CRF via multi-target mechanisms involving energy metabolism, tumor inhibition, and immune-inflammatory regulation, supporting its clinical use in CRF and potential as lung cancer adjuvant therapy.